You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.


Nevrargenics Ltd is a UK drug discovery and development company focused on innovative and novel medicines for neurodegenerative disease, the result of world-class research, developed through a commercial team to bring a series of drug solutions to market and to service disease areas of major unmet need. Two research groups based at Aberdeen and Durham Universities have been collaborating for several years, and through this collaboration, have designed, synthesized and identified a lead drug candidate with the potential for establishing new treatment approaches. Our strategy is to employ new dual-acting retinoic acid receptor modulators (RAR-M) as the basis for developing a series of new rationally designed, effective treatments, meeting that most severe of unmet needs.

Our strengths


We have a clear strategy of focusing on discovering and developing novel drugs and entering into corporate deals with pharma companies for finalising development and commercialisation.

Rich Pipeline

A strong patent portfolio of novel dual-acting drugs with potential applications in a number of disease areas, especially neurodegenerative diseases, but also diseases of the liver and the eye.

Experienced Team

We have experience of over 30 years' each and come from the pharma & biotech industry, science/medicine and finance. We have an entrepreneurial culture and a large network.

Contact us

We care

Our Vision & Values

Nevrargenics' vision is to become a successful biotech company with disruptive treatments to help millions of sufferers around the world, capitalizing on partnerships and delivering value to our shareholders.

We value innovation, creativity, integrity, commitment and fairness. We believe that success is driven by good people and diversity focusing on talent and experience. We are driven by passion and professionalism.

Our cutting edge research

Our research team has a long track record in RAR research: Modelling and designing small molecule synthetic drugs that target RARs; Studying their biological effects in retinoic acid signalling pathways gated by RARs; Impact upon controlling cellular development; Novel IP on novel dual-acting small molecule drugs developed; Identified lead candidates potentially valuable for treating closely linked neurological conditions characterised by degeneration of brain tissues and neurons; NVG0645 most advanced lead candidate – undergoing preclinical development studies shows exceptional CNS exposure and sub-nanomolar activity. Our drug candidates show exceptional ability to selectively control both genomic and non-genomic RAR-modulating pathways.

Alzheimer’s, Parkinson’s, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Frontotemporal Dementia, new drugs

Leadership & Management


Nevrargenics is managed and supported by an highly experienced Board of Directors, Scientific Advisory Board and Management Team, with each member typically having over 30 years' experience in its field of expertise.

Our team
Alzheimer’s, Parkinson’s, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Frontotemporal Dementia, new drugs

The meaning behind our name

We know our name is a little unusual, but it does have a rationale behind it!

The first part of our name comes from "nevra", the Greek word for nerves. The last part "genics" comes from "generation". Generating or growing nerves, is the target of our drugs. Importantly, even though it's difficult to pronounce, the middle of the name, "rar", is where our drugs act, the Retinoid Acid Receptors.

Our innovative research has been validated by many of the UK’s government funded research initiatives, reserved for the most innovative projects